The ongoing ‘ATTAINMENT’ study is a modular, multi-arm, first-in-human study to evaluate the safety and tolerability of MDX-124, alone and in combination with anti-cancer treatments, in participants with locally advanced, unresectable or metastatic solid malignancies.
Initial Phase 1b clinical data across a range of cancers show encouraging anti-tumour activity with no significant toxicity: View the clinical data >
The Recommended Phase 2 Dose has been established and efficacy is now being evaluated in specific tumour types, including biliary tract cancer and pancreatic cancer, both indications for which MDX-124 has received Orphan Drug Designation.
The Chief Investigator is Professor Daniel Palmer of the Liverpool Clinical Trial Centre. Patients are also being enrolled at the Early Phase Trials Unit (Oxford), the Edinburgh Cancer Research Centre, the Beatson West of Scotland Cancer Centre and The Christie (Manchester).
Find out more about the ATTAINMENT study via Cancer Research UK or the ISRCTN Registry.
MDX-124 has also shown considerable potential for the treatment of various autoimmune diseases and other conditions, and Medannex is planning further studies in these areas. In addition, Medannex is developing antibody-drug conjugates (ADCs) based on MDX-124.
